CINV=chemotherapy-induced nausea and vomiting.
MEC=moderately emetogenic chemotherapy.
HEC=highly emetogenic chemotherapy.
- SUSTOL is indicated for the prevention of CINV due to MEC and AC combination chemotherapy.1
- SUSTOL [package insert]. Heron Therapeutics, Inc., Redwood City, CA; August 2016.
- Aloxi [package insert]. Eisai Inc., Woodcliff Lake, NJ; December 2015.
- Zofran [package insert]. GlaxoSmithKline, Research Triangle Park, NC; September 2014.
- Kytril [package insert]. Genentech, Inc., South San Francisco, CA; April 2011.
- Sancuso [package insert]. ProStrakan Inc., Bridgewater, NJ; September 2014.
- Anzemet [package insert]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ; September 2014.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2017. © National Comprehensive Cancer Network, Inc., 2017. All rights reserved. Accessed April 20, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.